In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease

@article{Kuhl1999InVM,
  title={In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease},
  author={D. Kuhl and R. Koeppe and S. Minoshima and S. Snyder and E. Ficaro and N. Foster and K. Frey and M. Kilbourn},
  journal={Neurology},
  year={1999},
  volume={52},
  pages={691 - 691}
}
Objective: To validate an in vivo method for mapping acetylcholinesterase (AChE) activity in human brain, preparatory to monitoring inhibitor therapy in AD. Background: AChE activity is decreased in postmortem AD brain. Lacking a reliable in vivo measure, little is known about central activity in early AD, when the disease is commonly targeted by AChE inhibitor drug therapy. Methods: Intravenous N-[11C]methylpiperidin-4-yl propionate ([11C]PMP) served as an in vivo AChE substrate. AChE activity… Expand
Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique.
  • A. Nordberg
  • Psychology, Medicine
  • Progress in brain research
  • 2004
TLDR
The current developments based on novel technologies, such as positron emission tomography (PET) for directly imaging cholinergic neuroreceptors, enzymes or amyloid plaques, in addition to measuring cerebral blood flow and metabolic changes in the brain of Alzheimer's disease (AD) patients are presented. Expand
In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism
TLDR
There is a global reduction of cortical AChE activity in dementia, which was reduced significantly in all brain regions in demented subjects, whereas reduction of CMRGlc and CBF was more limited to temporo-parietal association areas. Expand
Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates.
TLDR
The method provides a quantitative measure of the cholinergic aspect of brain function and proved to be useful in diagnosis of neurodegenerative disorders including Alzheimer's disease. Expand
Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease
TLDR
Analysis of the cognitive data showed that mean cortical AChE activity was significantly associated with performance on a test of attention and working memory but not with tests of delayed short or long-term memory functions, compared to performance on primary memory tests in AD. Expand
Acetylcholine esterase activity in mild cognitive impairment and Alzheimer’s disease
  • K. Herholz
  • Medicine
  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2007
TLDR
The in vivo findings in MCI and very mild AD seem to suggest that cholinergic innervation and AChE as the main degrading enzyme are both reduced, which might result in partial compensation of their effect. Expand
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex
TLDR
Direct positron emission tomography measures of cerebral acetylcholinesterase activity were made in AD patients before and after treatment with donepezil and compared with similar measures in normal controls who were untreated or after acute administration of another AChE inhibitor, physostigmine salicylate. Expand
Acetate in Rats Compared With MP 4 A as a Probe for Measuring Cerebral Acetylcholinesterase Activity
C]MP4A is an established radioprobe for quantification of cerebral acetylcholinesterase (AChE) activity by positron emission tomography (PET) based on the kinetics of AChE-mediated metabolism andExpand
Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease
TLDR
Hippocampal acetylcholinesterase activity is only slightly reduced in mild cognitive impairment and early Alzheimer’s disease and so the value of in vivo acetylCholinestersterase measurements in detecting the early Alzheimer process is limited. Expand
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
TLDR
The treatment-specific increase in CSF ChAT activity suggests that cholinesterase-inhibitors may also increase the ACh-biosynthesis capacity in the patients. Expand
PET measurement of cerebral acetylcholine esterase activity without blood sampling
TLDR
A non-invasive method for quantitation of regional cortical AChE activity with carbon-11-labelled N-methyl-4-piperidyl acetate (11C-MP4A) that does not require arterial blood sampling is developed and tested and overcomes problems of the invasive technique. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 184 REFERENCES
Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease
TLDR
The method described for non-invasive in-vivo detection of regional acetylcholinesterase changes in the living human brain that is feasible for biochemical assessment of Alzheimer's disease is feasible. Expand
In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease
TLDR
It is concluded that cholinergic neuron integrity can be monitored in living AD and PD patients, and that it is not so devastated in vivo as suggested by postmortem choline acetylransferase activity. Expand
Convergent cholinergic activities in aging and Alzheimer's disease
TLDR
The normal aging human hippocampus may constitute a useful model for investigating the dysfunction or degeneration of basal forebrain cholinergic neurons in AD. Expand
Alzheimer's disease: Choline acetyltransferase activity in brain tissue from clinical and pathological subgroups
TLDR
Multivariate regression analysis showed myoclonus to be the single best predictor of low brain choline acetyltransferase activity in patients with Alzheimer's disease and a history of myOClonus. Expand
Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies
TLDR
Reductions in basal ganglia dopamine and HVA suggest that LBV cases have a level of dopamine depletion similar to Parkinson's disease (PD), which may have contributed to the absence of resting tremor and the milder presentation of parkinsonian features in this group compared with classic PD. Expand
A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer's disease.
In the brains of 21 patients with Alzheimer's disease (AD) and 10 nondemented controls, senile plaques (SPs), neurofibrillary tangles (NFTs), and three indexes of cholinergic function were quantifiedExpand
Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding
TLDR
The authors conclude that pixel-by-pixel-weighted integral analyses of NMPB distribution introduce transport biases into receptor-binding estimates, and similar confounding effects also are predicted in noncompartmental analyses of delayed radiotracer distribution. Expand
Neurochemical correlates of major depression in primary dementia.
TLDR
The results indicate that the development of major depression in primary dementia is associated with a profile of concurrent neurochemical changes that is largely consistent with existing neurochemical hypotheses of idiopathic affective disorders, and qualitatively distinct from that associated with primary dementia. Expand
Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo.
TLDR
Intra-brain distribution of the esters reflected a pattern of AchE activity, and showed a wide range of enzymatic reactivity, and high specificity for AchE except the butyrate. Expand
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.
TLDR
In the Lewy body cases neocortical choline acetyltransferase was consistently lower than in the classical Alzheimer's disease cases, and the combined data suggest that cholinergic therapy may be particularly relevant to patients withLewy body type dementia. Expand
...
1
2
3
4
5
...